AstraZeneca: Externally Sponsored Scientific Research (ESR) – Respiratory & Immunology Focus
Investigators may request supply of respiratory-and-immunology compounds—ranging from inhaled combinations (ICS/LABA/LAMA) to monoclonal antibodies—for mechanistic, preclinical, and clinical studies that elucidate disease biology, optimize treatment paradigms, and evaluate real-world outcomes in asthma, COPD, SLE, and related disorders.
Eligibility Criteria:
-
External researchers at respiratory or immunology research centres.
-
Proposals must align with the specified compound-centric areas of interest and local clinical-trial regulations.
Funding Details:
-
Support Type: Drug supply, PK/PD assay kits, mechanistic-model access, and real-world data tools.
-
Key Compounds & Interests:
-
Fasenra (benralizumab): Biomarker overlap, eosinophil-depletion effects, lifecycle-management in eosinophil-driven diseases.
-
Tezspire (tezepelumab): Mechanistic studies on TSLP in airway disease, digital-endpoint development, and registry analyses.
-
Saphnelo (anifrolumab): Organ-specific lupus response measures, patient-centric QOL tools, and interferon-driven pathology in non-rheumatologic diseases.
-
Airsupra/Breztri/Symbicort/Pulmicort/Sipavibart: Inhaled-therapy maintenance, exacerbation prevention, pMDI value, and safety/efficacy in special populations.
-
Deadline:
Rolling submissions via the ESR portal; contact company staff for pre-submission advice.
Where to Go for Further Information:
Access the ESR submission tool on AstraZeneca’s Open Innovation portal and liaise with the Respiratory & Immunology medical team.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023